Key Developments: Regulus Therapeutics Inc (RGLS.W)
7.06USD
2 May 2013
$0.59 (+9.12%)
$6.47
$7.06
$7.06
$7.06
100
35
$7.37
$4.42
Latest Key Developments (Source: Significant Developments)
Regulus Therapeutics Inc Announces Pricing of Initial Public Offering
Regulus Therapeutics Inc announced the pricing of its initial public offering of 11,250,000 shares of its common stock at $4.00 per share. Regulus has also granted the underwriters a 30-day option to purchase up to an additional 1,687,500 shares at the initial public offering price to cover overallotments, if any. Regulus' common stock is scheduled to begin trading on The NASDAQ Global Market on October 4, 2012 under the symbol RGLS. Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are acting as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow Life Sciences are acting as co-managers. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 4, 2012. Full Article
Regulus Therapeutics Inc Files Registration Statement For Proposed Initial Public Offering
Regulus Therapeutics Inc announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Regulus. The number of shares to be offered and the price range for the offering have not yet been determined. Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow Life Sciences are acting as co-managers. Full Article
Regulus Therapeutics Inc Sets Price Band For Initial Public Offering-MarketLine (a Datamonitor Company), Financial Deals Tracker
MarketLine (a Datamonitor Company), Financial Deals Tracker reported that Regulus Therapeutics Inc has set the price band for its proposed Initial Public Offering (IPO) of 4,545,454 shares of its common stock between $10 and $12 per share. Regulus has granted the underwriters the right for 30 days from the date of this prospectus to purchase up to an additional 681,818 shares of common stock, to cover over-allotments. Regulus intends to list its stock on the NASDAQ Global Market under the RGLS symbol. Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are acting as joint book-running managers, and Needham & Company, LLC and Wedbush PacGrow Life Sciences are acting as co-managers for the offering. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
